ISRCTN52245496已完成不适用
Does treatment with rosiglitazone result in improved pancreatic beta-cell function as compared to glimepiride in metformin treated diabetes type 2 patients?
Academic Medical Centre (AMC) (The Netherlands)0 个研究点目标入组 22 人开始时间: 2006年3月8日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 22
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Informed consent form signed
- •2. Type 2 diabetes patients, according to World Health Organization (WHO) criteria
- •3. Age 18 - 70 years
- •4. Use of metformin, at least 500 mg a day
- •5. HbA1c greater than 7.0% inclusive when on metformin alone, or greater than 6.5% when on combination therapy of metformin and a sulfonylurea derivative. Use of a sulfonylurea derivative is allowed, with a wash-out period of four weeks before the first assessments.
排除标准
- •1. Established coronary heart disease
- •2. Previous use of a thiazolidinedione
研究者
相似试验
暂停
不适用
Does treatment with rosiglitazone result in improved pancreatic beta-cell function as compared to glimepiride in metformin treated diabetes type 2 patients?NL-OMON27919Academic Medical Center - Amsterdam22
尚未招募
2 期
The effect of Rosiglitazone on negative symptoms in schizophreniaSchizophreniaIRCT20090117001556N159niversity of social welfare and rehabilitation sciences50
尚未招募
2 期
The effect of Rosiglitazone in the treatment of depressioIRCT20090117001556N152Tehran University of Medical Sciences50
已完成
不适用
A comparison of the effects of rosiglitazone on endothelial function and arterial stiffness in insulin resistant individuals and normal controlsCardiovascular: Endothelial function and arterial stiffnessCirculatory SystemEndothelial function and arterial stiffnessISRCTN50847630Record provided by the NHS Trusts Clinical Trials Register - Department of Health (UK)36
已完成
不适用
Effect of rosiglitazone, compared to sulphonylurea, on endothelial function in Chinese patients with type two diabetesType two diabetesNutritional, Metabolic, EndocrineDiabetes mellitusISRCTN05215453Hong Kong University Research Committee (Hong Kong)68